The epidemiology of the disease is strikingly concentrated in early childhood. Roughly 90 percent of pediatric cases present between the ages of 2 and 14, with a mean age of onset between 7.3 and 8.8 years. Clinicians classify morphea into several subtypes, including circumscribed plaque disease, linear morphea, generalized morphea, pansclerotic morphea, and mixed forms. Linear morphea is the most common subtype in children, and it is also among the most feared. When linear lesions cross the forehead and frontotemporal region, a presentation known as en coup de sabre, patients face a heightened risk of neurological involvement, facial asymmetry, and permanent deformity of the underlying skull and bone during critical growth windows. A related variant, Parry Romberg syndrome, can produce progressive hemifacial atrophy with or without visible skin hardening.

What makes morphea particularly dangerous in children is that it is not merely a skin disease. Approximately 20 percent of patients develop extracutaneous manifestations, including arthritis, uveitis, and neurological symptoms. Because the disease can scar actively growing bones and the developing skull, experts emphasize prompt and aggressive systemic treatment for deep or linear subtypes. Differentiating morphea from systemic sclerosis is also crucial: systemic sclerosis is characterized by sclerodactyly, Raynaud’s phenomenon, nail-fold capillary changes, telangiectasias, and internal organ involvement, features that generally distinguish it from the localized form. Interestingly, about half of morphea cases may undergo spontaneous resolution, complicating decisions about how intensively to treat.

The pathogenesis of morphea involves a complex interplay between genetic susceptibility, immune dysregulation, vascular injury, and aberrant fibrotic responses. Early lesions show a perivascular and interstitial inflammatory infiltrate of lymphocytes, macrophages, and plasma cells, accompanied by endothelial cell injury and microvascular dysfunction. Fibrosis itself is driven by persistent fibroblast activation and excessive deposition of type I and type III collagen. At the center of this process sits transforming growth factor-beta, or TGF-β, a master regulator that promotes fibroblast proliferation, drives differentiation into myofibroblasts, and boosts collagen synthesis while suppressing matrix degradation. Additional profibrotic mediators, including connective tissue growth factor, platelet-derived growth factor, and endothelin-1, amplify the fibrotic cascade.

Recent immunological insights have opened the door to precision therapies. A predominance of Th2-associated cytokines, particularly interleukin-4 and interleukin-13, promotes fibrosis through direct stimulation of fibroblast activity, and both cytokines signal through the Janus kinase-STAT pathway, especially STAT6. This provides a biological rationale for drugs targeting IL-4/IL-13 signaling, such as dupilumab, and for broader JAK-STAT inhibition. Even more dramatic was the discovery of novel gain-of-function STAT4 variants, inherited in an autosomal dominant manner or arising de novo, in children with disabling pansclerotic morphea, the most severe deep form of the disease. In a landmark study, four affected individuals from three families treated with oral ruxolitinib showed resolution of inflammatory biomarkers and clinical symptoms, with single-cell RNA sequencing revealing an immunodysregulatory signature that was effectively modulated by JAK inhibition.

For the majority of patients, treatment still follows a severity-based algorithm developed by the Childhood Arthritis and Rheumatology Research Alliance, or CARRA. Low-severity disease, defined as circumscribed superficial morphea without subcutaneous atrophy, extracutaneous involvement, or scalp hair loss, can be managed with high-potency topical corticosteroids, topical tacrolimus, calcipotriol, or imiquimod, often combined with phototherapy using broadband UVA, UVA1, or narrowband UVB. Tacrolimus ointment 0.1 percent demonstrated significant improvement in a randomized placebo-controlled trial after 12 weeks, while a case report of topical ruxolitinib cream 1.5 percent and another of the pan-JAK inhibitor delgocitinib in a 2-year-old suggest that topical JAK blockade may soon join the armamentarium. Imiquimod, an immune response modifier that induces interferon-gamma release and inhibits fibroblast collagen production, reduced lesion thickness in a prospective open-label study of nine children.

Moderate to severe disease demands systemic therapy, and methotrexate remains the undisputed first line. Dosing is calculated either by weight, at 0.3 to 0.6 mg/kg/week orally or up to 1 mg/kg/week subcutaneously, or by body surface area at 15 mg/m²/week, generally capped at 25 mg per week. Subcutaneous administration is often preferred for superior bioavailability and fewer gastrointestinal side effects. A systematic review found methotrexate effective in 93 percent of children, compared with 71 percent for phototherapy alone, and a randomized double-blind placebo-controlled trial showed that methotrexate combined with an initial prednisone course produced significantly better outcomes than placebo. Treatment is typically maintained for 12 to 24 months before tapering, and pulsed intravenous methylprednisolone may be added for severe or rapidly progressive cases, with side effects such as Cushingoid facies generally reversible after tapering.

For children who fail methotrexate, several alternatives have emerged. Mycophenolate mofetil achieved remission in 35 percent of patients within one year in a retrospective cohort, and in a separate study 90.9 percent of methotrexate-refractory children attained sustained remission over a mean follow-up of 9.4 years. Abatacept, which blocks T-cell costimulation, produced clinical improvement in 83 percent of eighteen refractory pediatric patients over 12 months, with some maintaining response to 24 months. Tocilizumab, an interleukin-6 receptor antagonist, significantly improved disease activity scores in five resistant patients after six months, though damage and quality-of-life measures did not change. Infliximab and the JAK inhibitors tofacitinib and baricitinib have each shown benefit in small case series, with tofacitinib reducing modified Localized Scleroderma Skin Activity Index and Damage Index scores without reported adverse effects.

The review’s authors caution that evidence for these emerging agents rests largely on case reports and small series, precluding definitive conclusions about comparative efficacy and long-term safety. Methotrexate and systemic corticosteroids remain the standard of care despite known risks including systemic toxicity and decreased bone density. Monitoring is especially critical in children, where corticosteroids can suppress growth velocity and bone mineral accretion. Objective assessment tools are improving: the Morphea Activity Measure correlates well with physician global assessments, and a novel multispectral imaging device using a handheld Antera 3D camera can predict new or enlarging lesions within three months with 90 percent sensitivity and 100 percent specificity, even in darkly pigmented skin. Ultrasound, magnetic resonance imaging, and 3D imaging add further objective windows into deep tissue involvement.

Finally, the review underscores that morphea is a whole-child disease. Although standardized quality-of-life instruments often show minimal impairment, qualitative studies of 690 pediatric patients across 13 studies reveal elevated stress, low self-worth, feelings of being different, and experiences of bullying tied to visible skin changes and treatment burden. The authors call for disease-specific psychosocial instruments, multidisciplinary care involving dermatology, rheumatology, physical therapy, psychology, and, for craniofacial disease, neurology, ophthalmology, and maxillofacial specialists, alongside standardized outcome metrics, robust disease registries, and personalized medicine approaches that tailor therapy to each child’s genetic and immunologic profile. As targeted therapies mature, the prospect of controlling fibrosis before it inflicts irreversible damage on growing bodies is moving steadily closer to reality.

Subject of Research: Advances in the diagnosis and treatment of pediatric morphea (localized scleroderma)

Article Title: Advances in the management of pediatric morphea: a narrative review

Article References: Kashyap, A., Jafari, A. J., Klimas, N., Koshelev, M., Mays, S. R., & Hebert, A. A. (2026). Advances in the management of pediatric morphea: a narrative review. Archives of Dermatological Research, 318(1), Article 448. https://doi.org/10.1007/s00403-026-04890-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04890-3

Keywords: pediatric morphea, localized scleroderma, autoimmune disease, methotrexate, JAK inhibitors, biologic therapy, fibrosis, STAT4, tocilizumab, abatacept, multidisciplinary care, skin disease